Brand Name
Lymphir
Generic Name
Denileukin Diftitox-Cxdl
View Brand Information FDA approval date: January 23, 2025
Classification: CD25-directed Cytotoxin
Form: Injection
What is Lymphir (Denileukin Diftitox-Cxdl)?
LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment